

SCIENTIFIC MEETING

15 min presentation each fellow + 5 min discussion

Tuesday, January 14th

09.00-09.05 Introduction

Alessio Nencioni - INTEGRATA coordinator - Department of Internal Medicine and Medical Specialities, UNIGE, Italy

SESSION I: Development and/or *in vitro* testing of new NAMPT and NAPRT inhibitors

09.05-09.25 Biochemical and cellular effects of NAPRT inhibitors in PDAC cells

Mochammad Ichan - Universitätsklinikum Bonn, Germany

09.25-09.45 Biochemical and cellular effects of NAMPT inhibitors in haematological cancer cells

Paulina Biniecka - Centre Hospitalier Universitaire Vaudois, Switzerland

09.45-10.05 New FK866 analogues, NAMPT inhibitors

Simone Fratta - Universidad de Sevilla, Spain

10.05-10.25 New compounds circumventing resistance to NAMPT inhibition

Ágata Carreira - Università degli Studi di Trento, Italy

10.25-10.45 New NAMPT inhibitors with imino-C-glycoside structures

Irene Conforti - Université de Montpellier, France

10.45-11.00 Break

11.00-11.20 New NAPRT inhibitors

Jorge Sus Franco - Innovamol Consulting, Italy

11.20-11.40 NAD precursor-depleted diets as a means to sensitize cancer cells to NAMPT inhibitors and chemotherapeutics

Moustafa Ghanem - Università degli Studi di Genova, Italy

SESSION II: Development and *in vitro* testing of ADCs of NAMPT inhibitors

11.40-12.00 ADCs of NAMPT inhibitors with anticancer activity

Pablo Ruedas Batuecas - Heidelberg Pharma Research GmbH, Germany

SESSION III: Development and *in vitro* testing of anti-eNAMPT and of anti-eNAPRT neutralizing Abs

12.00-12.20 Neutralizing anti-eNAMPT Abs

Elise Semerena - Novimmune - Light Chain Bioscience, Switzerland

12.20-14.00 *Lunch break*

SESSION IV: Development and *in vitro* testing of SIRT6, TRPM2, NUDT22 and CD73 inhibitors

14.00-14.20 New SIRT6 inhibitors

Elena Abbotto - Università degli Studi di Genova, Italy

14.20-14.40 New NUDT22 inhibitors

Melanie Walter - University of Sheffield, United Kingdom

14.40-15.00 New CD73 inhibitors

Benjamin Gyau - Università degli Studi di Torino, Italy

15.00-15.20 New TRPM2 inhibitors

Swati Balasheb Ohol - Universitätsklinikum Hamburg-Eppendorf, Germany

SESSION V: Fingerprinting/pre-formulation, formulation, PK and biodistribution studies of NAD-lowering compounds and inhibitors of NAD/nucleotide signalling

15.20-15.40 *In vivo* metastasis and angiogenesis imaging as a reading frame for NAMPT inhibitor activity

Cihat Burak Kizil - Université de Genève, Switzerland

15.40-15.50 *Break*

MANAGEMENT MEETING (15.50-17.00)

- Progress of the project
- Potential issues in project activities, go/no go decisions
- Possible project extension
- New schedule of secondments
- Next deadlines of the project
- Next training courses to be organised
- General discussion